Gilead Sciences has completed its $7.8-billion acquisition of Arcellx, a bio/pharmaceutical company focused on oncology. The deal was announced in February (February 2026). 

Kite, a subsidiary of Gilead Sciences, and Arcellx had an existing collaboration to co-develop and co-commercialize Arcellx’s lead pipeline candidate, anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for treating multiple myeloma.   

Under the agreement, a wholly-owned subsidiary of Gilead acquired approximately 77.1% of Arcelix’s common stock for $115 per share in cash plus one non-transferable contingent value right (CVR) for an additional $5 per CVR upon the achievement of cumulative global net sales of anito-cel of at least $6.0 billion from launch through year-end 2029.  

Source: Gilead Sciences